R-Pharm has recently released the latest findings from its Phase 3 open-label study (CREDO 4) on olokizumab in the esteemed European journal Annals of the Rheumatic Diseases. The study evaluated the safety and efficacy of olokizumab, a drug developed for treating rheumatoid arthritis. Based on a study involving 2,400 patients, the results demonstrate that the drug not only achieves a clinical response, but also maintains it for a minimum of two years. The safety and tolerability of olokizumab remained stable throughout the treatment period.
Mikhail Samsonov, the Medical Director of R-Pharm, emphasized that these findings confirm previous data on the effectiveness and safety of olokizumab, thus reinforcing its status as a viable treatment option for patients with rheumatoid arthritis. Olokizumab, marketed as Artlegia, is the first monoclonal antibody to be registered for the treatment of rheumatoid arthritis. Unlike other treatments, Artlegia specifically targets the cytokine IL-6, rather than its receptor. It is approved in Russia and several CIS countries and included in the clinical guidelines and essential drug lists.
